gastric cancer
Oncology · 2011–2026
13decisions
7medicines
6carried consumer input
4individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| durvalumab Perioperative treatment (neoadjuvant and adjuvant) of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma who are eligible for… | Mar 2026 | Recommended with restriction | no section in document |
| zolbetuximab First-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose… | Mar 2025 | Recommended with restriction | input received |
| trastuzumab deruxtecan Treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma following progression on prior… | Nov 2025 | Not recommended | input received Rare Cancers Australia |
| nivolumab Advanced or metastatic non-HER2 positive gastric cancer, gastro-oesophageal junction cancer, or oesophageal adenocarcinoma in combination with… | Mar 2022 | Recommended with restriction | 2 individuals Pancare Foundation · Medical Oncology Group |
| nivolumab Advanced or metastatic non-HER2 positive gastric cancer, gastro-oesophageal junction cancer, or oesophageal adenocarcinoma, in combination with… | Nov 2021 | Not recommended | 2 individuals Pancare Foundation · Medical Oncology Group |
| ramucirumab Treatment of patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and… | Jul 2019 | Not recommended | unclear |
| trastuzumab HER2-positive early breast cancer, locally advanced breast cancer, metastatic breast cancer, and advanced gastric cancer. | Jul 2019 | Recommended | none received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| trifluridine with tipiracil Extension to current listing for treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who… | Nov 2019 | Recommended with restriction | input received |
| ramucirumab Advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. | Mar 2018 | Recommended with restriction | input received Medical Oncology Group |
| trastuzumab Treatment of HER2 positive, metastatic (Stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have not received prior… | Jul 2015 | Recommended with restriction | none received |
| trastuzumab For the treatment of HER2 positive advanced (equivalent stage III or IV) adenocarcinoma of the stomach or gastro oesophageal junction, in patients who have not… | Nov 2012 | Deferred | unclear |
| trastuzumab Treatment of HER2 positive advanced (equivalent to stage III or IV) adenocarcinoma of the stomach or gastro-oesophageal junction, in patients who have not… | Jul 2011 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Pancare Foundation · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.